INTRODUCTION
Primary cutaneous lymphomas (PCL) are monoclonal lymphoproliferative processes that affect skin, without evidence of extracutaneous involvement at diagnosis. [1] [2] [3] This entity accounts for 18% of the extranodal non-Hodgkin lymphomas (NHL), being the skin the second most frequent location, following the gastrointestinal tract. 4, 5 Worldwide, its annual incidence is 0.5-1 per 100,000
habitants. 4 In Peru, 35% of NHL are extranodal. Of those, 10% to 15% are located on the skin. 6, 7 According to the cell of origin PCLs are classified as T-cell or B-cell (80% and 20%, respectively). 8 As primary cutaneous lymphomas constitute a heterogeneous and unusual group of diseases, they represent a diagnostic and therapeutic challenge. The correlation of clinical, pathological and immunophenotypic findings is imperative for its proper assessment and classification. 1 Many attempts have been made to establish a classification system for cutaneous lymphomas that is widely accepted. 9 In 2005, the World Health Organization (WHO) and the European Organization for Research and Treatment of Cancer (EORTC) together established a primary cutaneous lymphoma classification system based on phenotypic and molecular features that enable to group them according to their prognosis. 10 Regarding T-cell lymphomas, indolent entities with a good prognosis, whose five-years survival varies among 75% and 100% are: mycosis fungoides (MF) and its variants, CD30+ anaplastic large cell lymphoma, lymphomatoid papulosis and panniculitis-like T-cell lymphoma. Sézary syndrome, adult T-cell leukemia/lymphoma (ATLL), extranodal NK/T lymphoma (NTCL), nasal type and the peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) are recognized as aggressive enti- Descriptive analysis was performed through frequency distribution tables. For overall survival (OS), the follow-up period was defined as the time elapsed between date of diagnosis and date of death or last contact. Survival curves were estimated using the Kaplan-Meier method and differences among curves within different variables were established with the log-rank test. A level of p<0.05 was considered for significant differences. The statistical package SPSS (IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY:
IBM Corp) was used for data analysis.
RESULTS
During the assessment period, 115 patients diagnosed with cutaneous lymphoma were admitted. Eighty-six corresponded to cutaneous T-cell lymphomas; 20, to cutaneous B-cell lymphomas;
and, 9 to blastic plasmacytoid dendritic cell neoplasms. Three patients were excluded due to secondary cutaneous involvement and 9 because of the lack of histopathological diagnosis. The 74 PCT-CL cases with confirmed histopathological diagnosis were finally included ( Figure 1 ). 
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nance of T-cell lymphomas over B-cell type. 13, 14 However, an US epidemiological study based on the SEER data -which evaluated 3,884 cutaneous lymphoma according to the WHO-EORTC classification -found that only 71.3% of cases corresponded to T-cell lymphomas. 5 Our results, in accordance with previous regional studies, reaffirm that lymphoproliferative diseases distribution varies among geographical areas in relation to genetic and environmental factors. 15 MF is the most frequent cutaneous lymphoma in our country and worldwide. 3, 5, 11 It is a disease that typically affects elderly people (mean age at the time of diagnosis: 55-60 years) and exhibits an indolent course with a slow progression of years or decades, from patchy lesions to more infiltrated plaques and eventually to tumors, or a combination of these. Initial lesions are more likely to appear on the buttocks and other areas that are not exposed to sunlight. Tumors rarely appear at the beginning of the disease; therefore, when facing this scenario, another primary cutaneous lymphoma type should be considered in the differential diagnosis. At advanced stages of the disease, there might be also nodal or even visceral involvement.
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Five-year OS is over 80%. 5, 10 The present series reports that most of our cases corresponded to this entity. Our OS at five years was 75.6%, similar to the 77% reported in a Peruvian case series. 11 Disseminated disease, tumoral stage, and histologically documented nodal involvement are adverse prognosis factors for survival. 16, 17 Remarkably, ATLL and extranodal NTCL represented 18.9% and 4.1% of our cases, respectively, contrary to what is reported in
Western countries, where these lymphomas account for less than 1%.
5,10
HTLV-1 infection is necessary, yet not sufficient, to develop ATLL. This disease arises in 1% to 5% of seropositive individuals, usually after two decades of viral persistence. 10 An area is denominated endemic for this retrovirus when 2% to 10% of the healthy adult population is infected. 18 Around the world, Japan, the Caribbean islands, certain regions of Africa and South America (Brazil, Colombia and Peru) are considered endemic areas. 19 In our country, the mean prevalence in general population selected groups is 5.19%. 18 The ATLL high frequency found in this study reflects HTLV- 25 This is an aggressive entity that tends to disseminate and whose mean survival time is 15 months. 27 In our series, the three patients with cutaneous NTCL died before a year since diagnosis.
HVL is a rare NK/T lymphoma with variable behavior. 8 It mainly affects children and teenagers from Asia or Latin-American, although it may exceptionally affect adults. 28 Clinically, it is characterized by the presence of rash, edema, vesicles, ulcers, crusts and scars; particularly on the face and occasionally on the limbs. 28 There is a strong association with the latent infection caused by EBV, which is detected through in situ hybridization (ISH) or by polymerase chain reaction (PCR) in 80% to 100% of patients. 29 The four reported cases in the present series were 15, 17, 23 and 26 years old and represented a significant 5.4% of the patients of our study. Evolution of the disease was variable, with 3 patients still alive and one dying due to the disease. Further investigation is required in order to determine the optimal treatment for this pathology, and if there are differences in the biological behavior among the pediatric and adult patients.
The term PTCL-NOS is used to classify all those entities that do not fit in the other well-defined subtypes of T-cell lymphomas primary to the skin. It probably includes many entities, but for now, criteria and biomarkers in order to recognize them are lacking. It usually appears on adults, with solitary nodules, and more frequently, with generalized nodules or tumors. 30 In general, these cutaneous lymphomas have a poor prognosis. 31 In this series, they accounted for 23% of the cases with a 5-year OS of 19%. As in ATLL, we consider that within this group, patients who presented only with cutaneous disease but rapidly progressed into a systemic involvement were included. 
CONCLUSION
